Schultz, Neil M.
Penson, David F.
Wilson, Samuel
Song, Yan
Yang, Hongbo
Ramaswamy, Krishnan
Lowentritt, Benjamin
Funding for this research was provided by:
Astellas Pharma Inc., Northbrook, IL
Medivation LLC, a Pfizer Company, San Francisco, CA
Article History
First Online: 5 October 2019
Compliance with Ethical Standards
:
: This study was funded by Astellas Pharma Inc., Northbrook, IL, USA, and Medivation LLC, a Pfizer Company, San Francisco, CA, USA, the codevelopers of enzalutamide.
: Neil M. Schultz is an employee of Astellas and owns stock in Gilead Sciences and Shire. David F. Penson has served as a consultant for Astellas, Janssen, and Dendreon and has received research funding and travel and accommodation expenses from Astellas and Dendreon. Samuel Wilson is an employee of Astellas and owns stock in Baxter. Yan Song and Hongbo Yang are employees of Analysis Group, Inc., which has received consultancy fees from Astellas. Krishnan Ramaswamy is an employee of, and owns stock in, Pfizer. Benjamin Lowentritt is an employee of Chesapeake Urology and has served as a speaker and consultant for Astellas, Bayer, Dendreon, Janssen, Merck, Pfizer, and UroGen.
: A synopsis of the current research was presented in poster format at the 2019 ASCO Genitourinary Cancers Symposium, which took place in San Francisco, CA, USA, 14–16 February 2019.
: The data that support the findings of this study are available from IBM MarketScan Research Databases, but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available.
: Data were fully de-identified and compliant with the Health Insurance Portability and Accountability Act. No institutional review board approval or informed consent was required for this retrospective study.